Oppenheimer Survey of Patient Therapy Combinations Show Relypsa (RLYP) Concern Overblown
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall St loses over 1% amid fading rate-cut hopes
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steadies as US fuel demand concerns face Middle East supply risks
- Dollar sags after US GDP and inflation surprise, except against yen
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Relypsa (RLYP) PT Raised to $75 at Wedbush; Misunderstanding Creating Buying Opportunity
October 22, 2015 11:13 AM EDTWedbush analyst Liana Moussato reiterated an Outperform rating and boosted her price target on Relypsa, Inc. (NASDAQ: RLYP) to $75.00 (from $66.00) after the FDA announced approval of patiromer under the brand name Veltassa for the treatment of hyperkalemia.
"As we expected, the FDA approved the use of Veltassa, dosed orally once a day (QD), for the treatment of hyperkalemia. In our... More
Relypsa (RLYP) Pares Gains on Concerns about Veltassa's Label
October 22, 2015 8:14 AM EDTRelypsa (NASDAQ: RLYP) declined pre-market Thursday, reversing earlier gains following FDA approval of Veltassa. Declines appear related to concerns about the drug's label. Analysts at Morgan Stanley reportedly described the label as "highly restrictive" and said it will probably limit demand.
... MoreOppenheimer Remains Bullish on Relypsa (RLYP) Following FDA's Veltassa Approval
October 22, 2015 6:49 AM EDTOppenheimer reiterated an Outperform rating and $55.00 price target on Relypsa, Inc. (NASDAQ: RLYP) after the FDA approved Veltassa once-daily for the treatment of hyperkalemia. Veltassa is expected to be available in the US by the first week of January 2016.
Analyst Ling Wang commented,... More
UPDATE: Relypsa's (RLYP) Veltassa Approved by FDA
October 21, 2015 5:15 PM EDT(Updated - October 21, 2015 5:15 PM EDT)
Relypsa's (NASDAQ: RLYP) Veltassa approved by FDA.
Below is the release from the FDA:
The U.S. Food and Drug Administration today approved Veltassa (patiromer for oral suspension) to treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.
Too much potassium in the blood can lead to dangerous, even fatal, changes in heart rhythm, said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDAs Center for Drug... More
